Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: Systematic review and meta-analysis

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Salvo, Francesco ^a,b,c   Moore, Nicholas ^a,b,c,d   Arnaudl, Mickae ^a,b   Robinson, Philip ^d,e   Raschi, Emanuel ^f   De Ponti, Fabrizio ^f   Bégaud, Bernard ^a,b,c   Pariente, Antoine ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM U657   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Centre of Clinical Investigation Clinical Epidemiology   (France)

^e ADERA   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; LINAGLIPTIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FALLING; FEMALE; FRACTURE; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; ODDS RATIO; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84969786963     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i2231     Document Type: Article

References (59)

1. Kilbridge PM, Campbell UC, Cozart HB, Mojarrad MG. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc 2006;13:372-7. doi:10.1197/jamia.M2069.
2. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013;347:f4533. doi:10.1136/bmj.f4533.
3. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9. doi:10.1016/S0140-6736(09)61969-3.
4. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909. doi:10.1136/bmj.b4909.
5. Gerstein HC, Miller ME, Genuth S, et al. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28. doi:10.1056/ NEJMoa1006524.
6. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 2014;174:251-8. doi:10.1001/jamainternmed.2013.12956.
7. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12. doi:10.1056/NEJMsa1103053.
8. Gilbert RE, Krum H. Heart failure in diabetes: effects of antihyperglycaemic drug therapy. Lancet 2015;385:2107-17. doi:10.1016/ S0140-6736(14)61402-1.
9. Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab 2012;14:634-43. doi:10.1111/j.1463-1326.2012.01583.x.
10. Lorber D, Anderson J, Arent S, et al. American Diabetes Association. Diabetes and driving. Diabetes Care 2012;35(Suppl 1):S81-6. doi:10.2337/dc12-s081.
11. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 2014;10:711-22. doi:10.1038/nrendo.2014.170.
12. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care 2015;38:1583-91. doi:10.2337/dc15-0279.
13. Harrison TR. Harrison's principles of internal medicine.French 18th Edition. McGraw-Hill, 1970.
14. Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Handb Clin Neurol 2013;117:295-307. doi:10.1016/ B978-0-444-53491-0.00023-7.
15. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013;369:362-72. doi:10.1056/ NEJMra1215228.
16. Sen Gupta P, Green AN, Chowdhury TA. Hypoglycaemia. BMJ 2011;342:d567. doi:10.1136/bmj.d567.
17. Cove DH. Hypoglycaemia unawareness. BMJ 2011;342:d1474. doi:10.1136/bmj.d1474.
18. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARã agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-15. doi:10.1016/j.tem.2012.03.001.
19. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33. doi:10.7326/0003-4819-137-1-200207020-00009.
20. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-44. doi:10.1053/gast.2002.31068.
21. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?Regul Pept 2005;128:159-65. doi:10.1016/j. regpep.2004.06.001.
22. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-52. doi:10.1345/aph.17360.
23. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369. doi:10.1136/bmj.e1369.
24. Keating GM. Alogliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2015;75:777-96. doi:10.1007/ s40265-015-0385-y.
25. Forst T, Koch C, Dworak M. Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Curr Med Res Opin 2015;31:1079-84. doi:10.1185/03007995.2015.1039936.
26. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;(2):CD006739.
27. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1413-23. doi:10.1016/S0140-6736(13)61500-7.
28. Salvo F, Moore N, Pariente A. Linagliptin for elderly patients with type 2 diabetes. Lancet 2014;383:307. doi:10.1016/ S0140-6736(14)60103-3.
29. Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013;4:CD009008.
30. Takeda. Summary of Product Characteristics. Vipidia. Last access date 05/12/2014. Secondary Takeda. Summary of Product Characteristics. Vipidia. Last access date 05/12/2014. www.ema.europa.eu/docs/ en-GB/document-library/EPAR--Product-Information/ human/002182/WC500152271.pdf.
31. Ingelheim B. Summary of Product Characteristics. Trajenta. Last access date 05/12/2014. Secondary Boehringer Ingelheim. Summary of Product Characteristics. Trajenta. Last access date 05/12/2014. www.ema.europa.eu/docs/en-GB/document-library/EPAR-- Product-Information/human/002110/WC500115745.pdf.
32. AstraZeneca. Summary of Product Characteristics. Onglyza. Last access date 05/12/2014. Secondary AstraZeneca. Summary of Product Characteristics. Onglyza. Last access date 05/12/2014. www. ema.europa.eu/docs/en-GB/document-library/EPAR--Product- Information/human/001039/WC500044316.pdf.
33. Merck Sharp & Dohme. Summary of Product Characteristics. Januvia. Last access date 05/12/2014. Secondary Merck Sharp & Dohme. Summary of Product Characteristics. Januvia. Last access date 05/12/2014. www.ema.europa.eu/docs/en-GB/document- library/EPAR--Product-Information/human/000722/ WC500039054.pdf.
34. Novartis. Summary of Product Characteristics. Galvus. Last access date 05/12/2014. Secondary Novartis. Summary of Product Characteristics. Galvus. Last access date 05/12/2014. www.ema. europa.eu/docs/en-GB/document-library/EPAR--Product- Information/human/000771/WC500020327.pdf.
35. Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928.
36. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380-2. doi:10.1016/j. jclinepi.2010.09.011.
37. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. doi:10.1016/j.jclinepi.2010.07.015.
38. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100. doi:10.1371/journal.pmed.1000100.
39. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. doi:10.1016/0197-2456(86)90046-2.
41. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, Available from handbook.cochrane.org.
42. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58. doi:10.1002/sim.1186.
43. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. doi:10.1136/bmj.315.7109.629.
44. Schünemann HJ, Oxman AD, Vist GE, et al. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, Available from handbook.cochrane.org.
45. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395-406. doi:10.1111/j.1742-1241.2009.02143.x.
46. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047-56. doi:10.1111/j.1463-1326.2008.00859.x.
47. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45. doi:10.1111/j.1463-1326.2007.00744.x.
48. Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;89:216-23. doi:10.1016/j.diabres.2010.04.017.
49. Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2012;34:1909-19 e15.
50. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28:1352-61. doi:10.1111/j.1464-5491.2011.03387.x.
51. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-76. doi:10.1111/j.1463-1326.2008.01016.x.
52. Seino Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Investig 2012;3:517-25. doi:10.1111/j.2040-1124.2012.00226.x.
53. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. doi:10.1056/NEJMoa1305889.
54. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014;30:11-22. doi:10.1002/dmrr.2470.
55. Del Prato S, Taskinen MR, Owens DR, et al. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. J Diabetes Complications 2013;27:274-9. doi:10.1016/j.jdiacomp.2012.11.008.
56. A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea. Study number: NCT01128153, 2012.
57. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54. doi:10.1111/j.1463-1326.2011.01467.x.
58. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. doi:10.1056/NEJMoa1307684.
59. Hoffman RP. Sympathetic mechanisms of hypoglycemic counterregulation. Curr Diabetes Rev 2007;3:185-93. doi:10.2174/157339907781368995.